A 2024 study reported prevention and reversal of neuropathy measures after experimental AICAR exposure in mouse models of type 1 and type 2 diabetes. The work is useful mechanistic evidence, but it is not a human treatment result.
Evidence at a glance
- The experiments were performed in mice, not people.
- In high-fat-diet mice, the phosphorylated-to-total AMPK ratio increased about threefold and LC3-II increased about twofold.
- Mitochondrial respiration and nerve-function findings occurred alongside systemic effects on insulin sensitivity, glucose and lipid metabolism.
Study record
The authors measured nerve conduction, sensory behavior, mitochondrial respiration and markers associated with mitochondrial fission and autophagosome assembly. In the high-fat-diet model, ADP-stimulated state 3 respiration fell to 120 ± 20 nmol O₂/min, compared with 220 ± 20 in control-diet mice; the reported HFD+AICAR value was 240 ± 30.
Results in context
The same paper described reversal of established deficits in streptozotocin-diabetic mice. That result is biologically interesting, but an experimental animal exposure is not a human dose and should never be reformatted as one.
The intervention also changed insulin sensitivity, glucose metabolism and lipid metabolism. That makes it unsafe to describe every outcome as proof of a single AMPK-only mechanism.
What the evidence cannot establish
No participants, clinical endpoint or human safety dataset was included.
Multiple pathway and systemic effects limit single-mechanism attribution.
The paper does not validate the identity, purity, content or suitability of any catalog lot.
Sources & editorial method
The editorial workflow began with linked PubMed primary papers, systematic reviews, PubChem identity records and FDA/DailyMed regulatory records. Population or model, denominators, endpoints, numerical results, null findings, limitations and conflicts were extracted before drafting. AI-assisted drafting and original image generation were used; the final facts and evidence boundaries were checked against the linked records on 2026-09-02. This is not independent peer review.
3 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-09-02. Null results, study size, model/population limits and relevant conflicts are retained. This is not medical advice, a customer case or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- AICAR prevents and reverses diabetic polyneuropathy by regulating mitophagyExperimental study. 2024. PMID 39795939.
- AICAr, a Widely Used AMPK Activator with Important AMPK-Independent EffectsVišnjić D, et al. Cells. 2021. PMID 34064363.
- PubChem Acadesine recordIdentity, formula, mass and synonyms; CID 17513.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
